Oils4cure: finding an effective drug to alleviate Refractory Epilepsy, one of the most severe symptoms in the pathology of Tuberous Sclerosis

Project Information

oils4cure

Grant agreement ID: 190119321

DOI 10.3030/190119321

EC signature date 30 November 2023

Start date 1 December 2023

End date 30 November 2025

Funded under

• The European Innovation Council (EIC)

Total cost € 2 225 538,75

EU contribution € 1 557 877,13

Coordinated by

OILS4CURE SL
Spain

Project description

New hope for refractory epilepsy in tuberous sclerosis

Refractory epilepsy, particularly in paediatric patients with tuberous sclerosis, poses a significant challenge due to its resistance to standard treatments. Tuberous sclerosis is a rare genetic disorder that causes tumours to form in the brain and other organs, leading to severe, uncontrolled seizures. This condition severely impacts the quality of life for affected children and their families. Conventional treatments often fall short, highlighting the urgent need for more effective solutions. In this context, the EIC-funded OILS4CURE project, led by a Spanish biotech firm, is developing YCJ-01, a groundbreaking drug derived from medicinal cannabis extracts. Targeted specifically at managing epilepsy associated with tuberous sclerosis, this therapy offers new hope where traditional treatments have failed.

Objective

OILS4CURE is a Spanish biotech company dedicated to the research, development, production and commercialisation of medicinal products based on a medicinal cannabis extract. It is developing a drug to manage refractory epilepsy associated with tuberous sclerosis (YCJ-01) and another for Leukodystrophies (YCJ-02), both are paediatric rare diseases. This project only deals with the development of our first and most advanced therapy directed at tuberous sclerosis (TS).

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.

• medical and health sciences › basic medicine › neurology › epilepsy
• medical and health sciences › basic medicine › pathology

You need to log in or register to use this function

Keywords

• Orphan drug
• Rare diseases

Programme(s)

• HORIZON.3.1 - The European Innovation Council (EIC) Main Programme

Topic(s)

• HORIZON-EIC-2023-ACCELERATOROPEN-01 - EIC Accelerator Open 2023

Call for proposal

HORIZON-EIC-2023-ACCELERATOR-01

Funding Scheme

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Coordinator

OILS4CURE SL

• Net EU contribution: € 1 557 877,13
• Address: CALLE LOS YEBENES 47 ; 28047 MADRID ; Spain
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Region
  Comunidad de Madrid › Comunidad de Madrid › Madrid
• Region: Comunidad de Madrid › Comunidad de Madrid › Madrid
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 2 225 538,75